Brief: DURECT On Track To Report Data From Ongoing Phase 2b AHFIRM Trial In 2H 2023
10/04/2023 11:33
April 10 (Reuters) - DURECT Corp DRRX.O :
* DURECT ANNOUNCES PEER-REVIEWED ARTICLE ACCEPTED FOR
PUBLICATION
WITH ADDITIONAL DATA FROM PREVIOUSLY COMPLETED PHASE 2A STUDY OF
LARSUCOSTEROL IN ALCOHOL-ASSOCIATED HEPATITIS
* DURECT CORP - COMPANY ON TRACK TO REPORT DATA FROM ONGOING
PHASE
2B AHFIRM TRIAL IN 2H 2023
Source text for Eikon: ID:nPnbVw4hSa
Further company coverage: DRRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DURECT
See all newsBrief: Bausch Health Completes Acquisition Of Durect Corporation, Expanding Late-Stage Liver Disease Portfolio
Durect Corp Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Durect Bausch Health Extend Tender Offer Date To Aug 12 - SEC Filing
Durect Corp Expected To Post A Loss Of 12 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended March 31: Earnings Summary